Reportstack has announced a new market research publication on Qsymia (Obesity) - Forecast and Market Analysis to 2022. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.
Qsymia, a novel combination of two generically available drugs, was developed by California-based Vivus. Approved by the FDA in July 2012, this once-daily, FDC therapy was one of the first drugs to receive regulatory approval for the treatment of obesity in over a decade. This combination has the two-fold intention of reducing adverse effects with a lower dosage while achieving greater weight loss than with either drug alone.
Scope
- Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Qsymia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Qsymia from 2012 to 2022.
- Sales information covered for the US and Canada
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Qsymia performance
- Obtain sales forecast for Qsymia from 2012-2022 in the US and Canada)
Qsymia, a novel combination of two generically available drugs, was developed by California-based Vivus. Approved by the FDA in July 2012, this once-daily, FDC therapy was one of the first drugs to receive regulatory approval for the treatment of obesity in over a decade. This combination has the two-fold intention of reducing adverse effects with a lower dosage while achieving greater weight loss than with either drug alone.
Scope
- Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Qsymia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Qsymia from 2012 to 2022.
- Sales information covered for the US and Canada
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Qsymia performance
- Obtain sales forecast for Qsymia from 2012-2022 in the US and Canada)
To view the table of contents and know more details please visit Qsymia (Obesity) - Forecast and Market Analysis to 2022 report.
No comments:
Post a Comment